Clinical Trials Logo

Relapsed or Refractory Multiple Myeloma clinical trials

View clinical trials related to Relapsed or Refractory Multiple Myeloma.

Filter by:

NCT ID: NCT03859427 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

ARROW2
Start date: April 23, 2019
Phase: Phase 3
Study type: Interventional

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

NCT ID: NCT03837509 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Start date: June 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab, compared with daratumumab alone, in participants with relapsed or refractory multiple myeloma who have received at least 2 but not more than 5 prior lines of therapy.

NCT ID: NCT03815383 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Start date: February 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

NCT ID: NCT03751293 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Start date: November 30, 2018
Phase: Phase 1
Study type: Interventional

This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

NCT ID: NCT03512353 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Start date: July 5, 2018
Phase: Phase 2
Study type: Interventional

Describe the safety profile of carfilzomib plus dexamethasone regimen (Kd 56 mg/m2 twice weekly in cycles 1-6 followed by Kd 70 mg/m2 once weekly in cycles 7-12) in subjects with RRMM with 1-3 prior lines of therapy at study entry.

NCT ID: NCT03464916 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Start date: April 5, 2018
Phase: Phase 1
Study type: Interventional

The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.

NCT ID: NCT03158688 Active, not recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

CANDOR
Start date: June 13, 2017
Phase: Phase 3
Study type: Interventional

Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in patients with multiple myeloma who have relapsed after 1 to 3 prior therapies.

NCT ID: NCT02939183 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

INTREPID-1
Start date: January 17, 2017
Phase: Phase 1
Study type: Interventional

A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.

NCT ID: NCT02834364 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

GMMG-BIRMA
Start date: June 2016
Phase: Phase 2
Study type: Interventional

Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with Binimetinib (MEK162).

NCT ID: NCT02675452 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Start date: June 13, 2016
Phase: Phase 1
Study type: Interventional

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia